Table 3 Outcomes in patients with visceral disease by site

From: Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Outcome

AA+P

 

P

Lung metastases

(n=105)

 

(n=45)

Median OS, months

 

12.0

 
 

13.9

 

7.9

Median rPFS, months

 

3.8

 
 

5.6

 

2.8

PSA response rate, %

28.6

 

6.7

Liver metastases

(n=89)

 

(n=29)

Median OS, months

 

6.7

 
 

7.3

 

4.0

Median rPFS, months

 

2.8

 
 

2.8

 

2.8

PSA response rate, %

13.5

 

3.5

Measurable disease a

 Lung metastases

(n=74)

 

(n=27)

ORR, %

12.2

 

0

 Liver metastases

(n=73)

 

(n=23)

ORR, %

4.1

 

0

  1. Abbreviations: AA, abiraterone acetate; ORR, objective response rate; OS, overall survival; P, prednisone; rPFS, radiographic progression-free survival.
  2. aAt baseline.
Back to article page